Sumn Basal prolactin (PRL) and total lactogenic hormone (TLH) levels were measured using a new microbioassay (BA) and conventional immunoradiometric assay (IRMA) in patients with breast cancer and compared to an age-matched control group. No significant differences were found using the IRMA, but BA lactogenic levels were significantly elevated in breast cancer patients compared controls, leading to a markedly elevated BA IRMA ratio for both PRL (2.7 vs 1.4, P<0.0001) and TLH (2.8 vs 1.4. P<O.0001) which was greatest for postmenopausal women. Using the mean + 2 standard deviations as the upper limit of normal. there was no significant difference between breast cancer patients and controls for IRMA. but BA and BA IRMA PRL levels were elevated in 42% and 61% of the patients. respectively.
The pivotal role of prolactin in the development and growth of rodent mammarv tumours is now well established, but controversy remains on the role of the hormone in human breast cancer. The small differences in prolactin levels in breast cancer reported in some studies (Ohgo et al.. 1976 : Aldinger et al.. 1978 : Barni et al.. 1986 ) and the negative findings of others (Franks et al.. 1974 : Kwa et al., 1974 : Jones et al.. 1977 : Secreto et al.. 1983 ) may be partly explained by failure to adequately take into account the chronobiology of prolactin secretion. Also these conflicting reports have used a homologous radioimmunoassay based on the technique described by Sinha et al. (1973) to measure serum prolactin. which may not necessarily reflect the true biological activity of the hormone as expressed in a bioassay. A newly developed microbioassay for lactogenic hormone measurement was therefore used to examine prolactin and total lactogenic bioactivity in breast disease (Maddox et al.. 1989) . Specificity for the measurement of prolactin bioactivity is attained by the addition of an excess of anti-human growth hormone antiserum to the assay culture medium.
The circulating levels of basal prolactin and growth hormone in serum were determined both by the new microbioassav and conventional immunoassay (using a two-site immunoradiometric assay) in patients with breast cancer and agematched controls. 
Patients and methods

Patients
Microbioassav
Bioactive prolactin and total lactogenic hormone levels were determined by the method previously described (Maddox et al.. 1989 (1992) . 65, [456] [457] [458] [459] [460] ity, after which cell mass was determined using a Titertek Multiskan MCC 340. Serum sample unknowns were calculated from the standard curve of prolactin concentrations against optical density as the mean of triplicate readings. Samples without anti-hGH were used to give total lactogenic hormone levels whilst those with anti-hGH gave values for prolactin alone.
Immunoassav
Both assays for lactogenic hormones used a two-site immunoradiometric assay essentially using modification of a previously described technique (Addison & Hales. 1971) . with final values given as a mean of duplicate readings. Total lactogenic hormone levels were calculated by the addition of prolactin and growth hormone values. The working range of the prolactin immunoradiometric assay was 50 to 6.500 mU 11 (1.5-197.0ngml-') with a coefficient of variation of less than 10%. Assay sensitivity was 50 mU 1-1 (1.5 ng ml-1). The working range of the growth hormone assay was 0.5-34 mUl1' (0.25-17ngml-') with interassay and intra-assay variation <11% and the assay sensitivity was 0.04mUl-1 (0.02 ng ml-1).
Statistical analysis Statistical analysis was carried out using parametric tests for clinical data that was normally distributed (t-test) and nonparametric statistical tests for analysis of serum levels of lactogemnc hormones which were not normally distributed. The upper limit of normal for BA and BA IRMA prolactin levels was taken to be the mean + 2 standard deviations for basal levels from age-matched control groups.
Results
The mean age (± ls.d.) (Figure 1) . However. subgroup analysis showed that although this elevation of lactogenic bioactiv%ity in breast cancer was highly significant for postmenopausal ( Figure 4 ). However, breast cancer patients showed no correlation of basal BA or IRMA prolactin with age.
Discussion
This study has shown that in accordance with the observations of several authors (Franks et al.. 1974; Sheth et al.. 1975; Jones et al., 1977; Kwa et al., 1974) . basal serum levels of prolactin in patients with breast cancer are generally within the normal range as determined by radioimmunoassay. Anderson et al. (1989) have reported no significant difference in the levels of basal lactogenic hormones between women with familial breast cancer and controls using both the radioimmunoassay and the original Nb2 bioassay. However, the number of patients studied was smaller and the two assays were not standardised to one reference preparation. Also the double-antibody radioimmunoassay was used (not the twin-site immunoradiometric assay) which may have influenced their results (Rose et al., 1988 ). The present study shows prolactin and total lactogenic hormone levels measured by microbioassay to be significantly elevated in breast cancer patients. compared with an age-matched control group. The majority of lactogenic activity in serum has been shown to be due to bioactive prolactin with only a minimal contribution from growth hormone. This finding is reflected in a markedly elevated basal BA/IRMA ratio for prolaction and total lactogenic hormone, with 61% of breast cancer patients having a basal BAIIRMA prolactin ratio above the upper limit of normal. The absolute levels of basal bioactive prolactin in breast cancer, however, are only moderately elevated above the normal physiological range. This may reflect a long-term modulator control of prolactin in the The predominant prolactin moiety secreted by the pituitary is the monomer ('little' prolactin) , which constitutes about 90% of total human pituitary prolactin extract; 'big' and 'big big' prolactin comprising 10-20% and 1-8% of the total, respectively (Garmier, 1978) . There is evidence that the monomeric form may be more biologically active, measured by receptor binding activity, compared to the larger forms (Garnier et al., 1978; Farkouh et al., 1979 
